Alnylam Pharmaceuticals is a biotechnology business based in the US. Alnylam Pharmaceuticals shares (ALNY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $241.76 – an increase of 3.73% over the previous week. Alnylam Pharmaceuticals employs 2,230 staff and has a trailing 12-month revenue of around $2.2 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $241.76 |
|---|---|
| 52-week range | $141.98 - $304.39 |
| 50-day moving average | $254.22 |
| 200-day moving average | $249.27 |
| Wall St. target price | $304.87 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.18 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $241.76 from 2025-03-14
| 1 week (2025-03-07) | -1.13% |
|---|---|
| 1 month (2025-02-14) | -5.73% |
| 3 months (2024-12-17) | -1.95% |
| 6 months (2024-09-17) | -11.91% |
| 1 year (2024-03-15) | 61.96% |
|---|---|
| 2 years (2023-03-16) | 27.47% |
| 3 years (2022-03-16) | 52.08% |
| 5 years (2020-03-16) | 145.94% |
| Revenue TTM | $2.2 billion |
|---|---|
| Gross profit TTM | $1.9 billion |
| Return on assets TTM | -2.74% |
| Return on equity TTM | -1500.66% |
| Profit margin | -12.37% |
| Book value | $0.52 |
| Market Capitalization | $31.3 billion |
TTM: trailing 12 months
We're not expecting Alnylam Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Alnylam Pharmaceuticals's shares have ranged in value from as little as $141.98 up to $304.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alnylam Pharmaceuticals's is 0.391. This would suggest that Alnylam Pharmaceuticals's shares are less volatile than average (for this exchange).
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Check out the best-performing ETFs so far in 2025.